Cargando…
Can Aliskiren be Considered as a New Novel Drug for Hypertension?
Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blo...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671838/ https://www.ncbi.nlm.nih.gov/pubmed/26677425 http://dx.doi.org/10.7759/cureus.375 |
_version_ | 1782404461364248576 |
---|---|
author | Bhatti, Adnan Bashir Gazali, Zarine Anwar |
author_facet | Bhatti, Adnan Bashir Gazali, Zarine Anwar |
author_sort | Bhatti, Adnan Bashir |
collection | PubMed |
description | Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blocks the very first step in the RAS system. Multiple trials have been carried out debating the outcome of monotherapy and combination therapy with other classes of hypertensive drugs. Focus on compliance, adverse effects, and the cost have also been in the news. Extensive studies are still needed to justify the clinical use of a DRI in the effective treatment of hypertension. |
format | Online Article Text |
id | pubmed-4671838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-46718382015-12-16 Can Aliskiren be Considered as a New Novel Drug for Hypertension? Bhatti, Adnan Bashir Gazali, Zarine Anwar Cureus Internal Medicine Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blocks the very first step in the RAS system. Multiple trials have been carried out debating the outcome of monotherapy and combination therapy with other classes of hypertensive drugs. Focus on compliance, adverse effects, and the cost have also been in the news. Extensive studies are still needed to justify the clinical use of a DRI in the effective treatment of hypertension. Cureus 2015-11-04 /pmc/articles/PMC4671838/ /pubmed/26677425 http://dx.doi.org/10.7759/cureus.375 Text en Copyright © 2015, Bhatti et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Bhatti, Adnan Bashir Gazali, Zarine Anwar Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
title | Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
title_full | Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
title_fullStr | Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
title_full_unstemmed | Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
title_short | Can Aliskiren be Considered as a New Novel Drug for Hypertension? |
title_sort | can aliskiren be considered as a new novel drug for hypertension? |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671838/ https://www.ncbi.nlm.nih.gov/pubmed/26677425 http://dx.doi.org/10.7759/cureus.375 |
work_keys_str_mv | AT bhattiadnanbashir canaliskirenbeconsideredasanewnoveldrugforhypertension AT gazalizarineanwar canaliskirenbeconsideredasanewnoveldrugforhypertension |